Status: Recruiting
Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The purpose of the study is to assess the safety and efficacy of recombinant human parathyroid hormone for treatment of adynamic bone disorder in patients with chronic kidney disease.
Participants needed: 48
Trial details
Phase: Phase 4Age: 18-120Biological sex: AllType: InterventionalSponsor: Ditte HansenUpdated: Apr 23, 2024Locations: 4
Eligibility criteria
Age ≥18 years [+3]
Hypercalcemia defined as sustained ionized calcium >1.35 mmol/l [+20]